Just one week after directing agencies to accelerate American-based pharmaceutical manufacturing, President Donald Trump signed another executive order (EO) on May 12, 2025. This EO focused squarely on reducing the cost of prescription drugs for American patients and taxpayers. The two orders reflect a broader shift in U.S. pharmaceutical policy: a movement toward increasing domestic […]

How Shifting U.S. Policy Impacts Pharmaceutical Strategy On May 5, 2025, President Donald Trump signed an executive order, Promoting American-Made Prescription Drugs. While the policy is primarily focused on bolstering U.S.-based pharmaceutical manufacturing, its implications reach far beyond domestic borders. Pharmaceutical leaders around the globe, especially those managing complex, multi-country supply chains, should take note. […]

Tariffs are affecting many industries in 2025, and pharmaceuticals are not being spared. Although new U.S. tariffs on Chinese imports were briefly enacted this year, they were quickly placed on hold. This pause has not eliminated uncertainty. Instead, it has added to the broader sense of economic hesitation, especially in industries like pharmaceuticals that depend […]

In the increasingly complex world of global labeling, tracking changes across labeling content is more than a best practice—it’s a regulatory necessity. Health authorities around the globe are demanding more detailed accountability, documentation, and traceability of every change made throughout the product lifecycle. Staying compliant is a major challenge for many companies, especially those with […]